To include your compound in the COVID-19 Resource Center, submit it here.

Amgen, Teva hematology news

Teva and Amgen resolved patent litigation in the U.S. District Court for the Eastern District of Pennsylvania related to Teva's biologic of Amgen's Neupogen filgrastim. As

Read the full 267 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE